The recent FDA approval of topical JAK inhibitors for children 2 years or older marks a significant advancement in pediatric ...

Eichenfield said that depending on severity, atopic dermatitis treatment is begun right away in these younger patients ...

Experts discuss the foundational role of topical therapies in pediatric atopic dermatitis management, highlighting the ...

Please provide your email address to receive an email when new articles are posted on . Previously administered orally, brepocitinib proved to be effective and well tolerated as a topical formation in ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Incyte Corporation’s (NASDAQ:INCY) announced Opzelura (ruxolitinib) cream 1.5% for the short-term and non-continuous chronic treatment ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients taking dupilumab for atopic dermatitis ...

The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for individuals aged 12 years and over with moderate-to-severe atopic dermatitis. The new ...